GH Research Investor Relations Material

GH Research PLC is a clinical-stage biopharmaceutical company focused on developing innovative therapies for psychiatric and neurological disorders. The company's primary area of research is centered on 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT), a psychoactive compound, which is being developed for treating treatment-resistant depression (TRD) and other mental health conditions. GH Research's leading product candidate, GH001, is an inhalable form of mebufotenin, currently in Phase 2b clinical trials for TRD, as well as in earlier trials for Bipolar II disorder and postpartum depression. Additionally, the company is developing GH002, an intravenous formulation, and GH003, an intranasal product. The company is headquartered in Dublin, Ireland, and its shares are listed on the NASDAQ.